S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands
A legfontosabb adatok
- Ki végzi
- Dartmouth-Hitchcock Medical Center
- Hol
- Lebanon (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 4. fázis
- Résztvevők
- 40 fő vett részt
- Kezdés
- 2022. aug. 17.
- Befejezés
- 2025. ápr. 11.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- S-Adenosyl-L-Methionine (Sam-E)
- Placebo
- A regiszteradat frissítve
- 2025. július 16.
Ki vehet részt
- Életkor
- 40 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Current primary care provider within the Dartmouth Health system
- Office visit at Dartmouth Health in the past 3 years
- Participants must be 40 or older at the time of signing the informed consent
- Participants have discomfort or functional limitations of one or both hands AND either:; Objective findings of at least one hand meeting diagnostic criteria based on the American College of Rheumatology (ACR)* or; Existing radiographic evidence of osteoarthritis as judged by a radiologist
- Patients taking OTC or prescription analgesics who are willing to stop their current analgesics for two weeks prior to study entry and remain off those medications over the course of the study
- *Objective inclusion criteria (see poster schematic); Swelling or deformity of 2 of the following ten joints: the 2nd and 3rd distal interphalangeal (DIP) of each hand, the 2nd and 3rd proximal interphalangeal (PIP) of each hand, and the 1st carpometacarpal joints of both hands
Ki nem vehet részt
- Patients taking prescription medications other than NSAIDs for their OA who are unable to stop their medication
- Patients taking any of the following medications at study entry OR starting any of these medications during the study period:; daily opioids (including tramadol or buprenorphine); gabapentin or pregabalin; prednisone; Prescription NSAIDs that they are unable to stop or topical diclofenac; SNRI drugs (Effexor, Cymbalta, Fetzima, Pristiq)
- Patients with diagnoses of arthritis from conditions other than OA
- Patients with Bipolar Disorder
- The participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
- Patients whose symptomatic joint is an artificial joint
Helyszínek itt: Egyesült Államok
- Dartmouth Hitchcock Medical CenterLebanon, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this study is to demonstrate the feasibility of evaluating SAMe tolerability, analgesic benefits, and daily functional improvement in patients with osteoarthritis of the hands compared to placebo. The secondary objective of this study is to generate preliminary data on discomfort, function, quality of life in patients with osteoarthritis of the hands when taking SAMe compared to placebo.
A vizsgálat 2 csoportja
- S-Adenosyl-L-Methionine (SAMe)A vizsgált kezelés
Participants receive S-Adenosyl-L-Methionine (SAMe) 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
Kezelés: S-Adenosyl-L-Methionine (Sam-E) és Placebo
- PlaceboPlacebo, összehasonlításként
Participants receive identically appearing 400mg capsule orally twice daily for 8 weeks, followed by a 1 week washout period.
Kezelés: S-Adenosyl-L-Methionine (Sam-E) és Placebo
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- S-Adenosyl-L-Methionine (SAMe) vs Placebo for Discomfort and Functional Limitations Associated With Osteoarthritis of the Hands: a Pilot Study
- A regiszteradat frissítve
- 2025. július 16.